These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31202609)

  • 1. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence.
    Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gjuladin-Hellon T; Iheozor-Ejiofor Z; Gordon M; Akobeng AK
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD010233. PubMed ID: 31425621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate for maintenance of remission in Crohn's disease.
    Patel V; Wang Y; MacDonald JK; McDonald JW; Chande N
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006884. PubMed ID: 25157445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for maintenance of medically-induced remission in Crohn's disease.
    Gordon M; Sinopoulou V; Akobeng AK; Sarian A; Moran GW
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD012609. PubMed ID: 38372447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
    Peyrin-Biroulet L; Chapman JC; Colombel JF; Caprioli F; D'Haens G; Ferrante M; Schreiber S; Atreya R; Danese S; Lindsay JO; Bossuyt P; Siegmund B; Irving PM; Panaccione R; Cao Q; Neimark E; Wallace K; Anschutz T; Kligys K; Duan WR; Pivorunas V; Huang X; Berg S; Shu L; Dubinsky M;
    N Engl J Med; 2024 Jul; 391(3):213-223. PubMed ID: 39018531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease.
    Lev-Tzion R; Griffiths AM; Leder O; Turner D
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD006320. PubMed ID: 24585498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials.
    Duijvestein M; Jeyarajah J; Guizzetti L; Zou G; Parker CE; van Viegen T; VandeCasteele N; Khanna R; Van Der Aa A; Sandborn WJ; Feagan BG; D'Haens GR; Jairath V
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1121-1132.e2. PubMed ID: 31442599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions to increase patient and family involvement in escalation of care for acute life-threatening illness in community health and hospital settings.
    Mackintosh NJ; Davis RE; Easter A; Rayment-Jones H; Sevdalis N; Wilson S; Adams M; Sandall J
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012829. PubMed ID: 33285618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A; Al Lehaibi LH; Alomar M; Aldhuwayan F; Alshouish S; Al-Ali AY; Almudhry Z; Almulhim A; Althagafi A; Aldosari S; AlAmeel T
    Saudi J Gastroenterol; 2024 Sep; 30(5):324-334. PubMed ID: 39157885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Ferrante M; D'Haens G; Jairath V; Danese S; Chen M; Ghosh S; Hisamatsu T; Kierkus J; Siegmund B; Bragg SM; Crandall W; Durand F; Hon E; Lin Z; Lopes MU; Morris N; Protic M; Carlier H; Sands BE;
    Lancet; 2024 Dec; 404(10470):2423-2436. PubMed ID: 39581202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for treating lymphocytic colitis.
    Chande N; Al Yatama N; Bhanji T; Nguyen TM; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006096. PubMed ID: 28702956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.